MedTrace Logo

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

NCT04930055 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2206

Last updated 2023-05-19

No results posted yet for this study

Summary

The goals of this study are to assess initial or booster vaccine performance (safety and efficacy) and to collect serum and peripheral blood mononuclear cells (PBMCs) pre and post-vaccination to assess immune and other response parameters following immunization in cancer patients receiving either the Pfizer (BTN162b2), Moderna (mRNA-1273), or the Janssen (Ad26.COV2.S) vaccines.

Conditions

Interventions

BIOLOGICAL

COVID-19 Vaccination

Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Utpal Dave, MD · Indiana University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2021-11-01
Completion
2022-03-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930055 on ClinicalTrials.gov